Arecor Therapeutics plc (AIM:AREC)
London · Delayed Price · Currency is GBP · Price in GBX 62.50
0.00 (0.00%)
Jun 16, 2026, 8:00 AM GMT
Arecor Therapeutics Company Description
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom.
The company’s lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes.
It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Arecor Therapeutics plc
| Country | United Kingdom |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Sarah Howell |
Contact Details
Address: Chesterford Research Park Little Chesterford, CB10 1XL United Kingdom | |
| Phone | 44 1223 426 060 |
| Website | arecor.com |
Stock Details
| Ticker Symbol | AREC |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BMWLM973 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sarah Howell | Chief Executive Officer |
| David Ellam | Chief Financial Officer |